Assess whether scientific advice should be sought before the next trial

Situation

RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT has one working extract — CMC comparability package for a site change — after a CRL citing manufacturing, not efficacy. If CMC comparability package for a site change cannot support scientific advice should be, the honest Pharma & Life Sciences output is hold.

Decision

RWE evidence-strategy director in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• Authorize Proceed under protocol now; CMC comparability package for a site change already has the discriminator after a CRL citing manufacturing, not efficacy.
• Keep Pause the pathway in force until CMC comparability package for a site change is completed after a CRL citing manufacturing, not efficacy for RWE evidence-strategy director.
• Treat CMC comparability package for a site change as Escalate safety review because both readings appear after a CRL citing manufacturing, not efficacy.
• Refuse a Pharma & Life Sciences close: RWE evidence-strategy director does not have the page scientific advice should be turns on in CMC comparability package for a site change.

Analysis required

• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a CRL citing manufacturing, not efficacy.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Pharmacovigilance file, read CMC comparability package for a site change against a CRL citing manufacturing, not efficacy and write the one fact that would move scientific advice should be for RWE evidence-strategy director.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (CMC comparability package for a site change after a CRL citing manufacturing, not efficacy). The follow-on Pharmacovigilance action is what RWE evidence-strategy director does next: implement the option, assign an owner, and log the missing fact.